Skip to main content
SpringerLink
Log in

Acute Heart Failure and Systemic Diseases

  • Chapter
Acute Heart Failure

  • 2407 Accesses

Abstract

Acute heart failure in systemic lupus erythematosus (SLE) may result from myocarditis, endocarditis, systemic hypertension, coronary artery disease, and left ventricular dysfunction secondary to drug toxicity. Pericarditis is an early and common cardiac manifestation of active lupus. Moderate to severe pericardial disease is infrequent (1), and constrictive pericarditis is rare. Pericardial fluid is usually exudative (1), and may contain anti-DNA antibodies, with low complement levels. Treatment includes nonsteroidal antiinflammatory drugs (NSAIDs) or corticosteroids in mild pericarditis (2). In cardiac tamponade, higher corticosteroid doses are needed, and often intravenous bolus and invasive procedures (pericardiocentesis, pericardial window, or pericardial stripping) are considered. In patients with relapsing pericarditis, methotrexate, azathioprine, and intravenous immunoglobulins (IVIGs) may be beneficial.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Shearn MA. The heart in systemic lupus erythematosus. Am Heart J. 1959;58:452–66.

    Article  CAS  PubMed  Google Scholar 

  2. Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14:683–6.

    Article  CAS  PubMed  Google Scholar 

  3. Singh JA, Woodard PK, Davila-Roman VG, et al. Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report. Lupus. 2005;14:137–44.

    Article  CAS  PubMed  Google Scholar 

  4. Petri M. Cardiovascular systemic lupus erythematosus. In: Lahita RG, ed. Systemic Lupus Erythematosus. Amsterdam: Elsevier Academic Press, 2004:913–942.

    Chapter  Google Scholar 

  5. Heibel RH, O’Toole JD, Curtiss EI, et al. Coronary arteritis in systemic lupus erythematosus. Chest. 1976;69:700–3.

    Article  CAS  PubMed  Google Scholar 

  6. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399–406.

    Article  CAS  PubMed  Google Scholar 

  7. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2407–15.

    Article  CAS  PubMed  Google Scholar 

  8. Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol. 2005;19:823–38.

    Article  CAS  PubMed  Google Scholar 

  9. Wajed J, Ahmad Y, Durrington PN, et al. Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatology (Oxford). 2004;43:7–12.

    Article  CAS  Google Scholar 

  10. Naqvi TZ, Luthringer D, Marchevsky A, et al. Chloroquine-induced cardiomyopathy-echocardiographic features. J Am Soc Echocardiogr. 2005;18:383–7.

    Article  PubMed  Google Scholar 

  11. Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93:513–9.

    Article  CAS  PubMed  Google Scholar 

  12. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med. 1996;335:1424–30.

    Article  CAS  PubMed  Google Scholar 

  13. Roldan CA, Shively BK, Lau CC, et al. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol. 1992;20:1127–34.

    CAS  PubMed  Google Scholar 

  14. Schneider C, Bahlmann E, Antz M, et al. Images in cardiovascular medicine. Unusual manifestation of Libman-Sacks endocarditis in systemic lupus erythematosus. Circulation. 2003;107:e202–4.

    Article  PubMed  Google Scholar 

  15. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–11.

    Article  CAS  PubMed  Google Scholar 

  16. Tenedios F, Erkan D, Lockshin MD. Cardiac involvement in the antiphospholipid syndrome. Lupus. 2005;14:691–6.

    Article  CAS  PubMed  Google Scholar 

  17. Asherson RA, Cervera R. Unusual manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol. 2003;25:61–78.

    Article  PubMed  Google Scholar 

  18. Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003;12:518–23.

    Article  CAS  PubMed  Google Scholar 

  19. Erkan D, Roman MJ, Tenedios F, et al. Cardiac involvement in antiphospholipid syndrome. In: Doria A, Pauletto P, eds. Handbook of Systemic Autoimmune Diseases, vol 1. The Heart in Systemic Autoimmune Diseases. Amsterdam: Elsevier, 2004:213–225.

    Google Scholar 

  20. Bloom BJ, Smith RN. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-2002. A 17-year-old boy with acute mitral regurgitation and pulmonary edema. N Engl J Med. 2002;347:921–8.

    Article  PubMed  Google Scholar 

  21. Asherson RA. The catastrophic antiphospholipid (Asherson’s) syndrome in 2004-a review. Autoimmun Rev. 2005;4:48–54.

    Article  PubMed  Google Scholar 

  22. Nicola PJ, Crowson CS, Maradit-Kremers H, et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum. 2006;54:60–7.

    Article  PubMed  Google Scholar 

  23. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003;30:36–40.

    PubMed  Google Scholar 

  24. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737–45.

    Article  PubMed  Google Scholar 

  25. Chung ES, Packer M, Lo KH, Fasanmade AA, et al. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133–40.

    Article  CAS  PubMed  Google Scholar 

  26. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594–602.

    Article  CAS  PubMed  Google Scholar 

  27. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807–11.

    PubMed  Google Scholar 

  28. Goodson NJ. Cardiac involvement in rheumatoid arthritis. In: Doria A, Pauletto P, eds. Handbook of Systemic Autoimmune Diseases, vol 1. The Heart in Systemic Autoimmune Diseases. Amsterdam: Elsevier, 2004:121–143.

    Google Scholar 

  29. Guedes C, Bianchi-Fior P, Cormier B, et al. Cardiac manifestations of rheumatoid arthritis: a casecontrol transesophageal echocardiography study in 30 patients. Arthritis Rheum. 2001;45:129–35.

    Article  CAS  PubMed  Google Scholar 

  30. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–11.

    CAS  PubMed  Google Scholar 

  31. Bargout R, Kelly RF. Sarcoid heart disease: clinical course and treatment. Int J Cardiol. 2004;97:173–82.

    Article  PubMed  Google Scholar 

  32. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86–108.

    Article  CAS  PubMed  Google Scholar 

  33. Belhassen B, Pines A, Laniado S, et al. Failure of corticosteroid therapy to prevent induction of ventricular tachycardia in sarcoidosis. Chest. 1989;95:918–20.

    Article  CAS  PubMed  Google Scholar 

  34. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–10.

    Article  CAS  PubMed  Google Scholar 

  35. Yazaki Y, Isobe M, Hiramitsu S, et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol. 1998;82:537–40.

    Article  CAS  PubMed  Google Scholar 

  36. Hiraga H, Yuwai K, Hiroe M, et al. Guideline for Diagnosis of Cardiac Sarcoidosis: Study Report on Diffuse Pulmonary Diseases from the Japanese Ministry of Health and Welfare. Tokyo: Japanese Ministry of Health and Welfare, 1993:23–24.

    Google Scholar 

  37. Uemura A, Morimoto S, Hiramitsu S, et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138:299–302.

    Article  CAS  PubMed  Google Scholar 

  38. Fahy GJ, Marwick T, McCreery CJ, et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest. 1996;109:62–6.

    Article  CAS  PubMed  Google Scholar 

  39. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92:282–8.

    Article  PubMed  Google Scholar 

  40. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–98.

    PubMed  Google Scholar 

  41. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44:1030–6.

    PubMed  Google Scholar 

  42. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002;122:1895–901.

    Article  PubMed  Google Scholar 

  43. Valantine HA, Tazelaar HD, Macoviak J, et al. Cardiac sarcoidosis: response to steroids and transplantation. J Heart Transplant. 1987;6:244–50.

    CAS  PubMed  Google Scholar 

  44. Desai MY, Fallert MA. Rapidly progressing congestive heart failure due to cardiac sarcoidosis involving papillary muscles: a case report and brief review of the literature. Cardiol Rev. 2003;11:163–8.

    Article  PubMed  Google Scholar 

  45. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med. 2003;54:169–84.

    Article  CAS  PubMed  Google Scholar 

  46. Gotlib J, Cools J, Malone JM 3rd, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004;103:2879–91.

    Article  CAS  PubMed  Google Scholar 

  47. Blauwet LA, Breen JF, Edwards WD, et al. Atypical presentation of eosinophilic endomyocardial disease. Mayo Clin Proc. 2005:1078–84.

    Google Scholar 

  48. Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol. 2000;86:110–3.

    Article  CAS  PubMed  Google Scholar 

  49. Hassan WM, Fawzy ME, Al Helaly S, et al. Pitfalls in diagnosis and clinical, echocardiographic, and hemodynamic findings in endomyocardial fibrosis: a 25-year experience. Chest. 2005;128:3985–92.

    Article  PubMed  Google Scholar 

  50. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978;89:167–72.

    CAS  PubMed  Google Scholar 

  51. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714–6.

    Article  CAS  PubMed  Google Scholar 

  52. Lonzetti LS, Joyal F, Raynauld JP, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum. 2001;44:735–6.

    Article  CAS  PubMed  Google Scholar 

  53. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin North Am. 1996;22:841–60.

    Article  CAS  PubMed  Google Scholar 

  54. D’Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428–40.

    Article  PubMed  Google Scholar 

  55. Smith JW, Clements PJ, Levisman J, et al. Echocardiographic features of progressive systemic sclerosis (PSS). Correlation with hemodynamic and postmortem studies. Am J Med. 1979;66:28–33.

    Article  CAS  PubMed  Google Scholar 

  56. Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J. 1993;125:194–203.

    Article  CAS  PubMed  Google Scholar 

  57. Kahan A, Devaux JY, Amor B, et al. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med. 1986;314:1397–402.

    CAS  PubMed  Google Scholar 

  58. Kahan A, Nitenberg A, Foult JM, et al. Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum. 1985;28:637–46.

    Article  CAS  PubMed  Google Scholar 

  59. Ferri C, Giuggioli D, Sebastiani M, et al. Heart involvement and systemic sclerosis. Lupus. 2005;14:702–7.

    Article  CAS  PubMed  Google Scholar 

  60. Kostis JB, Seibold JR, Turkevich D, et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med. 1988;84:1007–15.

    Article  CAS  PubMed  Google Scholar 

  61. Hachulla E, Gressin V, Guillevin et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French Nationwide Prospective Multicenter Study. Arthritis Rheum 2005;52:3792–800.

    Article  PubMed  Google Scholar 

  62. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088–93.

    Article  CAS  PubMed  Google Scholar 

  63. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;123:344–50.

    Article  PubMed  Google Scholar 

  64. Ferri C, Di Bello V, Martini A, et al. Heart involvement in systemic sclerosis: an ultrasonic tissue characterisation study. Ann Rheum Dis. 1998;57:296–302.

    Article  CAS  PubMed  Google Scholar 

  65. Lindqvist P, Caidahl K, Neuman-Andersen G, et al. Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. Chest. 2005;128:755–63.

    Article  PubMed  Google Scholar 

  66. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81:139–53.

    Article  Google Scholar 

  67. Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med. 1976;295:1149–54.

    Article  CAS  PubMed  Google Scholar 

  68. Alpert MA, Goldberg SH, Singsen BH, et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation. 1983;68:1182–93.

    CAS  PubMed  Google Scholar 

  69. Oetgen WJ, Mutter ML, Lawless OJ, et al. Cardiac abnormalities in mixed connective tissue disease. Chest. 1983;83:185–8.

    Article  CAS  PubMed  Google Scholar 

  70. Kim P, Grossman JM. Treatment of mixed connective tissue disease. Rheum Dis Clin North Am. 2005;31:549–65.

    Article  PubMed  Google Scholar 

  71. Wiener-Kronish JP, Solinger AM, Warnock ML, et al. Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis. 1981;124:499–503.

    CAS  PubMed  Google Scholar 

  72. Burdt MA, Hoffman RW, Deutscher SL, et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 1999;42:899–909.

    Article  CAS  PubMed  Google Scholar 

  73. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898–909.

    Article  CAS  PubMed  Google Scholar 

  74. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047–60.

    Article  PubMed  Google Scholar 

  75. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141–57.

    Article  CAS  PubMed  Google Scholar 

  76. Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6:737–43.

    Article  CAS  PubMed  Google Scholar 

  77. Palka P, Lange A, Donnelly JE, et al. Doppler tissue echocardiographic features of cardiac amyloidosis. J Am Soc Echocardiogr. 2002;15:1353–60.

    Article  PubMed  Google Scholar 

  78. Klein AL, Hatle LK, Taliercio CP, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation. 1991;83:808–16.

    CAS  PubMed  Google Scholar 

  79. Klein AL, Hatle LK, Burstow DJ, et al. Comprehensive Doppler assessment of right ventricular dia stolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990;15:99–108.

    Article  CAS  PubMed  Google Scholar 

  80. Kim WH, Otsuji Y, Yuasa T, Minagoe S, Seward JB, Tei C. Evaluation of right ventricular dysfunction in patients with cardiac amyloidosis using Tei index. J Am Soc Echocardiogr 2004;17:45–9.

    Article  PubMed  Google Scholar 

  81. Patel AR, Dubrey SW, Mendes LA, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol. 1997 15;80:486–92.

    Article  Google Scholar 

  82. Lindqvist P, Olofsson BO, Backman C, et al. Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr. 2006;7:22–30.

    Article  CAS  PubMed  Google Scholar 

  83. Aprile C, Marinone G, Saponaro R, et al. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med. 1995;22:1393–401.

    Article  CAS  PubMed  Google Scholar 

  84. Lekakis J, Dimopoulos M, Nanas J, et al. Antimyosin scintigraphy for detection of cardiac amyloidosis. Am J Cardiol. 1997;80:963–5.

    Article  CAS  PubMed  Google Scholar 

  85. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186–93.

    Article  PubMed  Google Scholar 

  86. Pellikka PA, Holmes DR Jr, Edwards WD, et al. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med. 1988;148:662–6.

    Article  CAS  PubMed  Google Scholar 

  87. Hamer JP, Janssen S, van Rijswijk MH, et al. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J. 1992;13:623–7.

    CAS  PubMed  Google Scholar 

  88. Nicolosi GL, Pavan D, Lestuzzi C, et al. Prospective identification of patients with amyloid heart disease by two-dimensional echocardiography. Circulation. 1984;70:432–7.

    CAS  PubMed  Google Scholar 

  89. Dubrey SW, Cha K, Simms RW, et al. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol. 1996;77:313–5.

    Article  CAS  PubMed  Google Scholar 

  90. Kholova I, Niessen HW. Amyloid in the cardiovascular system: a review. J Clin Pathol. 2005;58:125–33.

    Article  CAS  PubMed  Google Scholar 

  91. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–96.

    Article  CAS  PubMed  Google Scholar 

  92. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.

    CAS  PubMed  Google Scholar 

  93. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–84.

    Article  CAS  PubMed  Google Scholar 

  94. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440–45.

    Article  CAS  PubMed  Google Scholar 

  95. Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978;52:818–27.

    CAS  PubMed  Google Scholar 

  96. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276–82.

    Article  CAS  PubMed  Google Scholar 

  97. Suhr OB, Svendsen IH, Andersson R, et al. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med. 2003;254:225–35.

    Article  CAS  PubMed  Google Scholar 

  98. Dubrey SW, Burke MM, Khaghani A, et al. Long term results of heart transplantation in patients with amyloid heart disease. Heart. 2001;85:202–7.

    Article  CAS  PubMed  Google Scholar 

  99. Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced longterm survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation. 1991;84(suppl):III338–43.

    CAS  PubMed  Google Scholar 

  100. Reveille JD. HLA-B27 and the seronegative spondyloarthropathies. Am J Med Sci. 1998;316:239–49.

    Article  CAS  PubMed  Google Scholar 

  101. Bergfeldt L. HLA-B27-associated cardiac disease. Ann Intern Med. 1997;127:621–9.

    CAS  PubMed  Google Scholar 

  102. O’Neill TW, King G, Graham IM, et al. Echocardiographic abnormalities in ankylosing spondylitis. Ann Rheum Dis. 1992;51:652–4.

    Article  PubMed  Google Scholar 

  103. Roldan CA, Chavez J, Wiest PW, et al. Aortic root disease and valve disease associated with ankylosing spondylitis. J Am Coll Cardiol. 1998;32:1397–404.

    Article  CAS  PubMed  Google Scholar 

  104. Peters MJ, Van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585–92.

    Article  PubMed  Google Scholar 

  105. Brunner F, Kunz A, Weber U, Kissling R. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population? Clin Rheumatol 2006;25:24–9.

    Article  PubMed  Google Scholar 

  106. Crowley JJ, Donnelly SM, Tobin M, et al. Doppler echocardiographic evidence of left ventricular diastolic dysfunction in ankylosing spondylitis. Am J Cardiol. 1993;71:1337–40.

    Article  CAS  PubMed  Google Scholar 

  107. Gould BA, Turner J, Keeling DH, et al. Myocardial dysfunction in ankylosing spondylitis. Ann Rheum Dis. 1992;51:227–32.

    Article  CAS  PubMed  Google Scholar 

  108. Shah A, Askari AD. Pericardial changes and left ventricular function in ankylosing spondylitis. Am Heart J. 1987;113:1529–31.

    Article  CAS  PubMed  Google Scholar 

  109. Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005;143:522–36.

    PubMed  Google Scholar 

  110. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the US preventive services task force. Ann Intern Med 2006;145:209–23.

    PubMed  Google Scholar 

  111. Olson LJ, Baldus WP, Tajik AJ. Echocardiographic features of idiopathic hemochromatosis. Am J Cardiol. 1987;60:885–9.

    Article  CAS  PubMed  Google Scholar 

  112. Cecchetti G, Binda A, Piperno A, et al. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation. Eur Heart J. 1991;12:224–30.

    CAS  PubMed  Google Scholar 

  113. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–9.

    Article  CAS  PubMed  Google Scholar 

  114. Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J. 2004;147:919–23.

    Article  PubMed  Google Scholar 

  115. Dabestani A, Child JS, Henze E, et al. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. Am J Cardiol. 1984;54:153–9.

    Article  CAS  PubMed  Google Scholar 

  116. Brandhagen DJ. Liver transplantation for hereditary hemochromatosis. Liver Transpl. 2001;7:663–72.

    Article  CAS  PubMed  Google Scholar 

  117. Caines AE, Kpodonu J, Massad MG, et al. Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transplant. 2005;24:486–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Non Invasive Echocardiography Laboratory, The European Hospital Georges Pompidou, Paris, France

    Iris Cohen MD

  2. Department of Cardiology-Internal Medicine, Fondation Ophtalmologique de Rothschild, Paris, France

    Nadia Benyounes-Iglesias MD

  3. Service de Medecine Interne, Hopital Beaujon, Assistance Publique Hôpitaux de Paris, Clichy, France

    Nadia Belmatoug

  4. Cardiology Department, Assistance-Publique-Hôpitaux de Paris, Saint-Antoine University and Medical School, Assistance Publique-Hôpitaux de Paris, Paris

    Ariel A. Cohen MD, PhD, FESC, FACC

  5. Université Pierre et Marie Curie, St-Antoine, Paris, France

    Ariel A. Cohen MD, PhD, FESC, FACC

Authors
  1. Iris Cohen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadia Benyounes-Iglesias MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nadia Belmatoug
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ariel A. Cohen MD, PhD, FESC, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Anesthesiology and Critical Care Medicine, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France

    Alexandre Mebazaa MD, PhD (Professor of Medicine) (Professor of Medicine)

  2. Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

    Mihai Gheorghiade MD, FACC (Professor of Medicine and Surgery, Associate Chief, Division of Cardiology and Chief, Cardiology Clinical Service) (Professor of Medicine and Surgery, Associate Chief, Division of Cardiology and Chief, Cardiology Clinical Service)

  3. Department of Cardiology Centre d’Investigation Clinique (CIC), INSERM U-684, Centre Hospitalier Universitaire, University Henri Poincaré, Nancy, France

    Faiez M. Zannad MD, PhD, FESC (Professor of Medicine) (Professor of Medicine)

  4. Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Camden, NJ, USA

    Joseph E. Parrillo MD (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director) (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director)

  5. Cooper Heart Institute, Cooper University Hospital, Camden, NJ, USA

    Joseph E. Parrillo MD (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director) (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Cohen, I., Benyounes-Iglesias, N., Belmatoug, N., Cohen, A.A. (2008). Acute Heart Failure and Systemic Diseases. In: Mebazaa, A., Gheorghiade, M., Zannad, F.M., Parrillo, J.E. (eds) Acute Heart Failure. Springer, London. https://doi.org/10.1007/978-1-84628-782-4_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-782-4_28

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-781-7

  • Online ISBN: 978-1-84628-782-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation